Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05558787
Other study ID # 113707
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 28, 2023
Est. completion date July 2025

Study information

Verified date December 2022
Source Radboud University Medical Center
Contact M. Beckers, MSc
Phone +31 (0) 24 361 33 92
Email parkinsoncentrum@radboudumc.nl
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rationale: Many persons with Parkinson's disease (PD) develop a progressive resistance to levodopa, which is the pharmacological mainstay of PD treatment. Recently, two enzymatic pathways have been identified that could be (partially) responsible for this: 1) breakdown of levodopa by bacterial tyrosine decarboxylase (TDC), an enzyme which normally decarboxylates dietary tyrosine but which is also able to decarboxylate levodopa. Accumulation of bacterial TDC in the small intestine, such as in the context of small-intestinal bacterial overgrowth (SIBO) - for which persons with PD are at increased risk - has the potential to prematurely metabolize levodopa, hence limiting its bioavailability and effect. 2) paradoxical induction of activity of the enzyme aromatic L-amino acid decarboxylase (AADC) in chronic users of levodopa combined with a peripheral decarboxylase inhibitor, also leading to a premature breakdown of levodopa and limitation of its bioavailability and effect. Primary objective: in a cross-sectional sample of advanced (≥5 years) Parkinson's disease determining the prevalence of increased bacterial TDC activity in feces, and the prevalence of increased AADC activity in serum. Secondary objective: correlating these biomarkers to clinical parameters, correlating composition of the microbiome to TDC activity, to the presence of levodopa resistance, and to factors related to socio-economic status. Study design: using feces, serum samples and clinical data from n=50 participants, the relevant enzymes' activity will be measured and the composition of the gut microbiome will be determined. These will be correlated to the clinical and demographic parameters.


Recruitment information / eligibility

Status Recruiting
Enrollment 50
Est. completion date July 2025
Est. primary completion date February 2024
Accepts healthy volunteers No
Gender All
Age group 25 Years and older
Eligibility Inclusion Criteria: - Participant has Parkinson's disease of at least 5 years duration, defined as time since diagnosis made by a neurologist; - Participant is an adult, at least 25 years of age; - Participant can read and understand Dutch; - Participant has completed the Ethics Committee-approved Informed Consent; - Participant is willing, competent, and able to comply with all aspects of the protocol, including not taking their PD medication during a 12-hour period, and biospecimen collection. Exclusion Criteria: - Co-morbidities that would hamper interpretation of parkinsonian disability, such as coincident musculoskeletal abnormalities, as judged by the investigators; - Significant doubt over the correctness of the diagnosis PD, as judged by the investigators; - Not able to stand or walk without the assistance of another person (walking aids are not an exclusion criterion); - Never having used levodopa; - No current use of levodopa due to lack of effect, despite never having used at least 600mg/day during at least 1 month; - Documented allergic reaction or severe side effect to levodopa or benserazide; - History of narrow-angle glaucoma (unless specific permission by the treating ophthalmologist for use of levodopa/benserazide); - History of malignant melanoma (unless specific permission by the treating dermatologist for use of levodopa/benserazide); - History of psychiatric disease with a psychotic component (unless specific permission by the treating psychiatrist for use of levodopa/benserazide); - Known current uncompensated cardiovascular, endocrine, renal, hepatic, hematologic, or pulmonary disease (unless specific permission by the treating physician for use of levodopa/benserazide); - Documented severe and debilitating dyskinesias on levodopa, to such an extent that levodopa treatment was terminated; - Current pregnancy or breastfeeding; - Co-morbidity with primary gastrointestinal pathology associated with altered gut microbiota and/or altered absorption (such as inflammatory bowel disease, celiac disease, colorectal carcinoma); - Antibiotic use at any time during the 12 months leading up to the clinic visit; - Current or recent (less than 1 month before clinic visit) use of (non-parkinson) drugs known or suspected to influence AADC activity, including amphetamine, dexamethasone, dopamine receptor antagonists, monoamine oxidase (MAO) inhibitors (including MAO-B inhibitors which are infrequently used as antiparkinsonian drugs), prostaglandin E2, and vigabatrin.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Netherlands Radboudumc Centre of Expertise for Parkinson & Movement Disorders Nijmegen

Sponsors (7)

Lead Sponsor Collaborator
Radboud University Medical Center Maag Lever Darm Stichting, ParkinsonNL, Predica Diagnostics, Stichting Alkemade-Keuls, Stichting Woelse Waard, University of Groningen

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of TDC activity in feces through study completion, an average of 2 weeks
Primary Prevalence of AADC activity in serum through study completion, an average of 2 weeks
Secondary Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part III Baseline score and score after levodopa administration through study completion, an average of 2 weeks
Secondary Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) part IV Baseline score and score after levodopa administration through study completion, an average of 2 weeks
Secondary Timed up-and-go test TUG. Baseline score and score after levodopa administration through study completion, an average of 2 weeks
Secondary Purdue Pegboard Test Baseline score and score after levodopa administration through study completion, an average of 2 weeks
Secondary Composite Clinical Motor Score This is a composite of MDS-UPDRS-III, TUG and pegboard test scores. Baseline score and score after levodopa administration. through study completion, an average of 2 weeks
Secondary modified Hoehn & Yahr score Ordinal scale of Parkinson's disease severity. Baseline score and score after levodopa administration. through study completion, an average of 2 weeks
Secondary 9-item Wearing-Off Questionaire (WOQ-9) Questionnaire on wearing-off symptoms through study completion, an average of 2 weeks
Secondary SIBO questionnaire 15-item scale on gastrointestinal symptoms associated with small-intestinal bacterial overgrowth (SIBO) through study completion, an average of 2 weeks
Secondary Schwab and England Activities of Daily Living Scale Single-question scale on the ability to perform activities of daily living through study completion, an average of 2 weeks
Secondary Medication questionnaire 9-item questionnaire on (current and past) medication use for Parkinson's disease, and their effect on symptoms through study completion, an average of 2 weeks
Secondary Demographics questionnaire 14-item questionnaire on demographic parameters through study completion, an average of 2 weeks
Secondary Diet questionnaire 18-item questionnaire on diet through study completion, an average of 2 weeks
See also
  Status Clinical Trial Phase
Completed NCT05415774 - Combined Deep Brain Stimulation in Parkinson's Disease N/A
Recruiting NCT04691661 - Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease Phase 2
Active, not recruiting NCT05754086 - A Multidimensional Study on Articulation Deficits in Parkinsons Disease
Completed NCT04045925 - Feasibility Study of the Taïso Practice in Parkinson's Disease N/A
Recruiting NCT04194762 - PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation N/A
Completed NCT02705755 - TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH) Phase 2
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT05830253 - Free-living Monitoring of Parkinson's Disease Using Smart Objects
Recruiting NCT03272230 - Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System N/A
Recruiting NCT06139965 - Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
Completed NCT04580849 - Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease N/A
Completed NCT04477161 - Effect of Ketone Esters in Parkinson's Disease N/A
Completed NCT03980418 - Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam N/A
Completed NCT04942392 - Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic N/A
Terminated NCT03446833 - LFP Beta aDBS Feasibility Study N/A
Completed NCT03497884 - Individualized Precise Localization of rTMS on Primary Motor Area N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT04997642 - Parkinson's Disease and Movement Disorders Clinical Database
Completed NCT04117737 - A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson N/A
Recruiting NCT03618901 - Rock Steady Boxing vs. Sensory Attention Focused Exercise N/A